Phase I Study of Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
Condition: Metastatic Breast Cancer Interventions: Biological: huMNC2-CAR44 CAR T cells; Biological: huMNC2-CAR44 CAR T cells @ RP2D Sponsors: Minerva Biotechnologies Corporation; Fred Hutchinson Cancer Research Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials